Valneva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.02.25	Shareholding declaration Valneva SE - January 2025 (GlobeNewswire)
05.02.25	Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire)
30.01.25	Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million (GlobeNewswire)
22.01.25	Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision (GlobeNewswire)
21.01.25	Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot (Benzinga)
20.01.25	Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine (GlobeNewswire)
06.01.25	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference (GlobeNewswire)
03.01.25	VALNEVA Declaration of shares and voting rights: December 31, 2024 (GlobeNewswire)
19.12.24	Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India (GlobeNewswire)
05.12.24	VALNEVA - Declaration of shares and voting rights: November 30, 2024 (GlobeNewswire)
04.12.24	Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal (GlobeNewswire)
03.12.24	Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® (GlobeNewswire)
26.11.24	Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA (GlobeNewswire)
13.11.24	Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 (GlobeNewswire)
12.11.24	Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences (GlobeNewswire)
07.11.24	Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06.11.24	VALNEVA - Declaration of shares and voting rights: October 31, 2024 (GlobeNewswire)
06.11.24	Ausblick: Valneva stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
23.10.24	Erste Schätzungen: Valneva vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
21.10.24	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
16.10.24	Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V (GlobeNewswire)
11.10.24	Expert Ratings For Valneva (Benzinga)
10.10.24	Valneva Hosts Investor Day in New York City (GlobeNewswire)
04.10.24	Valneva SE - Declaration of shares and voting rights - September 30, 2024 (GlobeNewswire)
03.10.24	Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET (GlobeNewswire)
25.09.24	In-Depth Examination Of 6 Analyst Recommendations For Valneva (Benzinga)
18.09.24	Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada (GlobeNewswire)
13.09.24	Valneva Announces the Success of its Private Placement Raising approximately €60 Million (GlobeNewswire)
12.09.24	Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros (GlobeNewswire)
04.09.24	VALNEVA - Declaration of shares and voting rights: August 31, 2024 (GlobeNewswire)
03.09.24	Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study (Benzinga)
03.09.24	The Analyst Landscape: 6 Takes On Valneva (Benzinga)
03.09.24	Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine (MarketWatch)
03.09.24	Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
14.08.24	Analyst Scoreboard: 8 Ratings For Valneva (Benzinga)
13.08.24	Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
12.08.24	Ausblick: Valneva legt Quartalsergebnis vor (finanzen.net)
06.08.24	VALNEVA - Declaration of shares and voting rights: July 31, 2024 (GlobeNewswire)
01.08.24	Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate (GlobeNewswire)
29.07.24	Erste Schätzungen: Valneva legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
22.07.24	What Analysts Are Saying About Valneva Stock (Benzinga)
22.07.24	CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine (GlobeNewswire)
17.07.24	Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion (GlobeNewswire)
04.07.24	Declaration of shares and voting rights - Valneva SE - June 30, 2024 (GlobeNewswire)
01.07.24	Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire)
26.06.24	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

08.02.25		BioNTech-Aktie: Experten empfehlen BioNTech im Januar mehrheitlich zum Kauf
07.02.25		Minuszeichen in New York: Das macht der Dow Jones nachmittags
07.02.25		Börse Frankfurt in Rot: TecDAX zeigt sich zum Ende des Freitagshandels leichter
07.02.25		Börse Frankfurt in Rot: MDAX zeigt sich zum Handelsende schwächer
07.02.25		Verluste in Europa: STOXX 50 zeigt sich letztendlich leichter
07.02.25		Schwache Performance in London: FTSE 100 schwächelt schlussendlich
07.02.25		Handel in Frankfurt: DAX präsentiert sich zum Ende des Freitagshandels leichter

08.02.25

BioNTech-Aktie: Experten empfehlen BioNTech im Januar mehrheitlich zum Kauf

07.02.25

Minuszeichen in New York: Das macht der Dow Jones nachmittags

07.02.25

Börse Frankfurt in Rot: TecDAX zeigt sich zum Ende des Freitagshandels leichter

07.02.25

Börse Frankfurt in Rot: MDAX zeigt sich zum Handelsende schwächer

07.02.25

Verluste in Europa: STOXX 50 zeigt sich letztendlich leichter

07.02.25

Schwache Performance in London: FTSE 100 schwächelt schlussendlich